+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Acne Vulgaris - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 119 Pages
  • December 2024
  • Region: Global
  • DelveInsight
  • ID: 4330799
UP TO OFF until Dec 31st 2024

Key Highlights

  • In 2023, there were approximately 29.43 million diagnosed prevalent cases of acne vulgaris in the 7MM, these cases are further expected to increase during the forecast period (2024-2034).
  • Factors contributing to the rise of diagnosed prevalent cases of acne vulgaris include hormonal changes, dietary influences, genetic predisposition, and environmental factors such as pollution.
  • The total diagnosed prevalence of acne vulgaris in the 7MM is expected to increase at a CAGR of 0.4% owing to changes in lifestyles, diet and escalated changes in the hormonal levels.
  • The Age-specific prevalent cases of acne vulgaris are divided into the following groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, a higher number of cases were observed in the age group 15-19 years compared to others, comprising around 5.85 million cases in 2023.
  • Among EU4 and the UK, Germany had the highest diagnosed prevalent population of acne vulgaris, with 3,486,784 cases, followed by France and Italy in 2023.
  • As per estimates, Japan accounted for nearly 10% of the Total Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM in 2023.
The “Acne Vulgaris - Epidemiology Forecast - 2034” report delivers an in-depth understanding of Acne Vulgaris, historical and forecasted epidemiology of Acne Vulgaris in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Acne Vulgaris Disease Understanding

Acne Vulgaris Overview

Acne vulgaris is a chronic inflammatory dermatological condition characterized by pimples, blackheads, and whiteheads on the skin, primarily affecting pilosebaceous units across various age groups, with adolescents being the most commonly affected demographic. The severity of acne can be classified into mild, moderate, and severe based on the presence of non-inflammatory and inflammatory lesions, erythema, and scarring. The pathogenesis involves a multifactorial interplay of hormonal influences, sebum production, follicular hyperkeratinization, bacterial proliferation, and inflammation, exacerbated by genetic predisposition, medications, and environmental factors. Key symptoms include comedones, inflammatory lesions, and scarring. The management of acne is challenging due to various risk factors, emphasizing the need for comprehensive understanding and targeted interventions.

Acne Vulgaris Diagnosis

Diagnosis of acne vulgaris typically involves a thorough clinical examination of the skin to assess the type, severity, and distribution of lesions. In some instances, additional diagnostic procedures are employed to rule out other skin conditions or determine bacterial involvement. These procedures include skin biopsies and microbial cultures. Furthermore, additional tests such as microbial testing, hormonal evaluations, and liver function tests may be conducted in specific cases to provide a comprehensive understanding of the condition.

Acne Vulgaris Epidemiology

For the purpose of designing the patient-based model for the Acne Vulgaris epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Prevalent Cases of Acne Vulgaris, Diagnosed Prevalent Cases of Acne Vulgaris, Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris, Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris, and Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
  • In 2023, an estimated ~140,217 thousand prevalent cases of Acne Vulgaris occurred across the 7MM, with approximately 69.50 million cases attributed to the US alone. These numbers are expected to increase steadily throughout the forecast period.
  • The categorization based on gender, showed that diagnosed prevalent cases in females were higher than in males in the 7MM. The female-diagnosed prevalent cases accounted for 63% of the total cases in the 7MM.
  • The prevalent cases of acne vulgaris were sub-segmented further based on the severity of the acne as mild, moderate, and severe. In 2023, the highest diagnosed prevalent cases of acne vulgaris were reported as moderate (45%), whereas there were least cases in the severe (10%) segment in the 7MM.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Wake Forest University School of Medicine, North Carolina; Department of Dermatology and Venereology, University Clinic Hamburg-Eppendorf, Hamburg, Germany; La Roche-Posay Pharmaceutical Laboratory, France; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Acne Vulgaris, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Acne Vulgaris Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Total Prevalent Cases of Acne Vulgaris
  • Total Diagnosed Prevalent Cases of Acne Vulgaris
  • Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris
  • Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris
  • Age-specific Diagnosed Prevalent Cases of Acne Vulgaris

Acne Vulgaris Report Key Strengths

  • 11 years Forecast
  • The 7MM Coverage
  • Acne Vulgaris Epidemiology Segmentation

Acne Vulgaris Report Assessment

  • Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Acne Vulgaris? What will be the growth opportunities across the 7MM concerning the patient population of Acne Vulgaris?
  • What is the historical and forecasted Acne Vulgaris patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • Why is the diagnosed prevalent cases of Acne Vulgaris in Japan lower than the US?
  • Which country has a high patient share for Acne Vulgaris?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Acne Vulgaris prevalence cases in varying geographies over the coming years.
  • A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Acne Vulgaris, along with diagnosed prevalence of Acne Vulgaris Based on severity of airflow limitation and diagnosed prevalence of Acne Vulgaris based on symptoms and exacerbation history.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Acne Vulgaris Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Acne Vulgaris cases in 2023?

The highest cases of Acne Vulgaris was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Acne Vulgaris cases in 2023?

The highest cases of Acne Vulgaris were found in the US among the 7MM in 2023.

Table of Contents

1. Key Insights2. Report Introduction
3. Acne Vulgaris Epidemiology Overview at a Glance
3.1. Patient Share Distribution of Acne Vulgaris in 2020
3.2. Patient Share Distribution of Acne Vulgaris in 2034
4. Epidemiology Forecast Methodology5. Executive Summary6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Types of Acne Vulgaris
7.3. Causes and Risk Factors
7.4. Pathophysiology
7.5. Symptoms and Clinical Presentations
7.6. Diagnosis
7.6.1. Diagnostic Algorithm
7.6.2. Differential Diagnosis
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. Prevalence of Acne Vulgaris
8.2.2. Diagnosed Prevalence of Acne Vulgaris
8.2.3. Severity-specific Diagnosed Prevalence of Acne Vulgaris
8.2.4. Gender-specific Diagnosed Prevalence of Acne Vulgaris
8.2.5. Age-specific Diagnosed Prevalence of Acne Vulgaris
8.3. Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM
8.4. The United States
8.4.1. Total Prevalent Cases of Acne Vulgaris in the US
8.4.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in the US
8.4.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US
8.4.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US
8.4.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US
8.5. EU4 and the UK
8.5.1. Germany
8.5.1.1. Total Prevalent Cases of Acne Vulgaris in Germany
8.5.1.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in Germany
8.5.1.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany
8.5.1.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany
8.5.1.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany
8.5.2. France
8.5.2.1. Total Prevalent Cases of Acne Vulgaris in France
8.5.2.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in France
8.5.2.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in France
8.5.2.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in France
8.5.2.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in France
8.5.3. Italy
8.5.3.1. Total Prevalent Cases of Acne Vulgaris in Italy
8.5.3.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in Italy
8.5.3.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy
8.5.3.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy
8.5.3.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy
8.5.4. Spain
8.5.4.1. Total Prevalent Cases of Acne Vulgaris in Spain
8.5.4.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in Spain
8.5.4.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain
8.5.4.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain
8.5.4.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain
8.5.5. The United Kingdom
8.5.5.1. Total Prevalent Cases of Acne Vulgaris in the UK
8.5.5.2. Total Diagnosed Prevalent Cases of Acne Vulgaris in the UK
8.5.5.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK
8.5.5.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK
8.5.5.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK
8.6. Japan
8.6.1. Total Prevalent Cases of Acne Vulgaris in Japan
8.6.2. Diagnosed Prevalent Cases of Acne Vulgaris in Japan
8.6.3. Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan
8.6.4. Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan
8.6.5. Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan
9. Patient Journey10. KOL Views
11. Appendix
11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of Epidemiology (2020-2034)
Table 2: Key Events
Table 3: Diagnosed Prevalent Cases of Acne Vulgaris In the 7MM (2020-2034)
Table 4: Total Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Table 5: Total Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Table 6: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Table 7: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Table 8: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Table 9: Total Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Table 10: Total Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Table 11: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Table 12: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Table 13: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Table 14: Total Prevalent Cases of Acne Vulgaris in France (2020-2034)
Table 15: Total Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Table 16: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Table 17: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Table 18: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Table 19: Total Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Table 20: Total Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Table 21: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Table 22: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Table 23: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Table 24: Total Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Table 25: Total Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Table 26: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Table 27: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Table 28: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Table 29: Total Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Table 30: Total Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Table 31: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Table 32: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Table 33: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Table 34: Total Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Table 35: Total Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Table 36: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Table 37: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Table 38: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Table 39: Total Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Table 40: Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Table 41: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Table 42: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Table 43: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
List of Figures
Figure 1: Acne Vulgaris
Figure 2: Formation of Acne Vulgaris
Figure 3: Types of Acne Vulgaris
Figure 4: Risk Factors of Acne Vulgaris
Figure 5: Clinical Presentation of Acne Vulgaris
Figure 6: Diagnostic Algorithm for Acne Vulgaris
Figure 7: Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM (2020-2034)
Figure 8: Total Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Figure 9: Total Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Figure 10: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Figure 11: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Figure 12: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the US (2020-2034)
Figure 13: Total Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Figure 14: Total Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Figure 15: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Figure 16: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Figure 17: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Germany (2020-2034)
Figure 18: Total Prevalent Cases of Acne Vulgaris in France (2020-2034)
Figure 19: Total Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Figure 20: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Figure 21: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Figure 22: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in France (2020-2034)
Figure 23: Total Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Figure 24: Total Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Figure 25: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Figure 26: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Figure 27: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Italy (2020-2034)
Figure 28: Total Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Figure 29: Total Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Figure 30: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Figure 31: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Figure 32: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Spain (2020-2034)
Figure 33: Total Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Figure 34: Total Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Figure 35: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Figure 36: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Figure 37: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the UK (2020-2034)
Figure 38: Total Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Figure 39: Total Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Figure 40: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Figure 41: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Figure 42: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in EU4 and the UK (2020-2034)
Figure 43: Total Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Figure 44: Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Figure 45: Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Figure 46: Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)
Figure 47: Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in Japan (2020-2034)